slotkoers
Andere beurzen
|
||
- CHF | - |
31/05 | NOVARTIS AG : UBS handhaaft koopadvies | ZD |
31/05 | Europese aandelen sluiten hoger in de vrijdaghandel; Flash-inflatie eurozone stijgt meer dan verwacht | MT |
Omzet 2024 * | 49,08 mld. 44,26 mld. 45,26 mld. | Omzet 2025 * | 51,18 mld. 46,15 mld. 47,19 mld. | Marktkapitalisatie | 210 mld. 190 mld. 194 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 10,48 mld. 9,45 mld. 9,67 mld. | Nettowinst (verlies) 2025 * | 11,74 mld. 10,59 mld. 10,83 mld. | EV/omzet 2024 * | 4,53 x |
Nettoschuld 2024 * | 12,07 mld. 10,88 mld. 11,13 mld. | Nettoschuld 2025 * | 10,61 mld. 9,57 mld. 9,79 mld. | EV/omzet 2025 * | 4,32 x |
K/w-verhouding 2024 * |
20
x | K/w-verhouding 2025 * |
17,3
x | Werknemers | - |
Dividendrendement 2024 * |
3,51% | Dividendrendement 2025 * |
3,64% | Vrij verhandelbaar | 85,22% |
Recentste transcriptie over Novartis AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-01-05 | |
Director of Finance/CFO | 59 | 01-01-03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01-01-13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28-02-20 |
Chairman | 68 | 01-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,73% | 739 mld. | |
+32,83% | 598 mld. | |
-6,30% | 353 mld. | |
+15,15% | 318 mld. | |
+4,05% | 285 mld. | |
+15,00% | 240 mld. | |
-5,52% | 206 mld. | |
+6,17% | 164 mld. | |
-0,45% | 162 mld. |
- Beurs
- Aandelen
- Koers NOVN
- Koers